System and method for non-invasive monitoring of hemoglobin

US11039768B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11039768-B2
Application numberUS-201815866036-A
CountryUS
Kind codeB2
Filing dateJan 9, 2018
Priority dateJan 9, 2018
Publication dateJun 22, 2021
Grant dateJun 22, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A method of non-invasively monitoring hemoglobin concentration includes providing incident light to patient tissue at a first excitation wavelength. The method further includes monitoring a first emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond with a maximum of the emission response, and monitoring a second emission response at a second emission wavelength, wherein the second emission wavelength is selected to correspond with a minimum of the emission response. A hemoglobin concentration is calculated based on a ratio of the first emission response to the second emission response.

First claim

Opening claim text (preview).

The invention claimed is: 1. A system for non-invasive monitoring of hemoglobin concentration level, the system comprising: a medical device comprising: at least one light source configured to provide light to patient tissue; a first photodetector configured to monitor an emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond with a maximum of the emission response of a hemoglobin component, wherein the hemoglobin component comprises at least one of oxyhemoglobin or de-oxyhemoglobin; and a second photodetector configured to monitor the emission response at a second emission wavelength, wherein the second emission wavelength is selected to correspond with a minimum of the emission response of the hemoglobin component; and one or more processors configured to receive the emission responses at the first emission wavelength and the second emission wavelength, wherein the one or more processors are configured to calculate a ratio based on the received emission responses and utilize the calculated ratio to determine the hemoglobin concentration level. 2. The system of claim 1 , wherein the hemoglobin component is oxyhemoglobin and the hemoglobin concentration level is an oxyhemoglobin concentration level, wherein the first emission wavelength is selected to correspond with a maximum of an oxyhemoglobin emission response and the second emission wavelength is selected to correspond with a minimum of the oxyhemoglobin emission response. 3. The system of claim 1 , wherein the hemoglobin component is de-oxyhemoglobin and the hemoglobin concentration level is a de-oxyhemoglobin concentration level, wherein the first emission wavelength is selected to correspond with a maximum of a de-oxyhemoglobin emission response and the second emission wavelength is selected to correspond with a minimum of the de-oxyhemoglobin emission response. 4. The system of claim 1 , wherein the one or more processors are configured to control generation of an alert in response to the hemoglobin concentration level falling below a threshold value, indicating anemia or change in the hemoglobin component. 5. The system of claim 1 , wherein the hemoglobin concentration level is determined in real-time or near real-time by the one or more processors. 6. The system of claim 1 , wherein the one or more processors are configured to collect and store a plurality of determined hemoglobin concentration levels over a first monitoring period, and provide an output of trends in monitored hemoglobin concentration levels. 7. The system of claim 1 , wherein the medical device further includes sensors for monitoring physiological parameters associated with the patient, including one or more of electrocardiogram (ECG) signals, respiration rates, bio-impedance levels, activity level, postures, or temperature. 8. The system of claim 7 , wherein the one or more processors are configured to utilize at least one of the monitored physiological parameters in combination with stored hemoglobin concentration levels to determine a patient condition. 9. The system of claim 1 , wherein the hemoglobin component comprises a first hemoglobin component and the ratio comprises a first ratio, the system further comprising a third photodetector configured to monitor the emission response at a third emission wavelength, wherein the third emission wavelength is selected to correspond with a maximum of the emission response of a second hemoglobin component, and wherein the one or more processors are configured to: receive the emission response at the third emission wavelength; calculate a second ratio based on the third emission response; and determine the hemoglobin concentration level based on a combination of the first ratio and the second ratio. 10. A method of non-invasively monitoring hemoglobin concentration level, the method comprising: providing incident light to patient tissue at a first excitation wavelength; monitoring an emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond with a maximum of the emission response of a hemoglobin component, wherein the hemoglobin component comprises at least one of oxyhemoglobin or de-oxyhemoglobin; monitoring the emission response at a second emission wavelength, wherein the second emission wavelength is selected to correspond with a minimum of the emission response of the hemoglobin component; and calculating the hemoglobin concentration level based on a ratio of the emission response measured at the first emission wavelength to the emission response measured at the second emission wavelength. 11. The method of claim 10 , wherein the hemoglobin component is oxyhemoglobin and the hemoglobin concentration level is an oxyhemoglobin concentration level, wherein the first emission wavelength is selected to correspond with a maximum of an oxyhemoglobin emission response and the second emission wavelength is selected to correspond with a minimum of the oxyhemoglobin emission response. 12. The method of claim 10 , wherein the hemoglobin component is de-oxyhemoglobin and the hemoglobin concentration is a de-oxyhemoglobin concentration, wherein the first emission wavelength is selected to correspond with a maximum of a de-oxyhemoglobin emission response and the second emission wavelength is selected to correspond with a minimum of the de-oxyhemoglobin emission response. 13. The method of claim 10 , further including detecting anemia based on the calculated hemoglobin concentration level falling below a threshold level. 14. The method of claim 10 , wherein the monitoring and calculating a hemoglobin concentration level is performed in real-time or near real-time. 15. The method of claim 10 , further including monitoring physiological parameters associated with the patient, including one or more of electrocardiogram (ECG) signals, respiration rates, bio-impedance levels, activity level, postures, or temperature. 16. The method of claim 15 , further including utilizing at least one of the monitored physiological parameters in combination with stored hemoglobin concentration levels to determine a patient condition. 17. The method of claim 10 , wherein the hemoglobin component comprises a first hemoglobin component and the ratio comprises a first ratio, the method further comprising: monitoring the emission response at a third emission wavelength, wherein the third emission wavelength is selected to correspond with a maximum of the emission response of a second hemoglobin component; and calculating a second ratio based on the third emission response; and wherein calculating the hemoglobin concentration level comprises calculating the hemoglobin concentration level based on a combination of the first ratio and the second ratio.

Assignees

Inventors

Classifications

  • for measuring blood gases · CPC title

  • Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction · CPC title

  • Clamps or clips · CPC title

  • for measuring analytes not otherwise provided for, e.g. ions, cytochromes · CPC title

  • Special features of optical sensors or probes classified in A61B5/00 · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11039768B2 cover?
A method of non-invasively monitoring hemoglobin concentration includes providing incident light to patient tissue at a first excitation wavelength. The method further includes monitoring a first emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond with a maximum of the emission response, and monitoring a second emission response at a…
Who is the assignee on this patent?
Medtronic Monitoring Inc
What technology area does this patent fall under?
Primary CPC classification A61B5/14551. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).